Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc-by (c)  Bouzón-Arnáiz, I. et al., 2025
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/217990

YAT2150 is irresistible in <em>Plasmodium falciparum</em> and active against <em>Plasmodium vivax</em> and <em>Leishmania </em>clinical isolates

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

We recently characterized the potent antiplasmodial activity of the aggregated protein dye YAT2150, whose presumed mode of action is the inhibition of protein aggregation in the malaria parasite. Using single-dose and ramping methods, assays were done to select Plasmodium falciparum parasites resistant to YAT2150 concentrations ranging from 3× to 0.25× the in vitro IC50 of the compound (in the two-digit nM range) and performed a cross-resistance assessment in P. falciparum lines harboring mutations that make them resistant to a variety of antimalarial drugs. Resistant parasites did not emerge in vitro after 60 days of incubation, which postulates YAT2150 as an ‘irresistible’ antimalarial. The lyophilized compound is stable for at least one year stored at 25 °C. Tests performed in clinical isolates indicated that YAT2150 had also strong activity against Plasmodium vivax (IC50 between 4 and 36 nM) and Leishmania infantum (1.27 and 1.11 µM), placing it as a unique compound with perspectives of becoming the first drug to be used against both malaria and leishmaniasis.

Citation

Citation

BOUZÓN ARNÁIZ, Xavier, et al. YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates. Scientific Reports. 2025. Vol. 15. ISSN 2045-2322. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/217990

Export metadata

JSON - METS

Share record